be beneficial for NSCLC patients with specific EZH2 mutations. EGFR, TP53, BRAF, SMARCA4 gene accompanied may have less correlation with EZH2 mutation in NSCLC patients. The findings of this study could facilitate both clinical trial design and therapeutic strategies.
significantly inhibited epithelial to mesenchymal transition and downregulated the expression of AKT, Stat3, and PD-L1. Conclusion: ASI treatment influences survival in stage IIIA NSCLC. Losartan improves the anti-tumor effect of cytotoxic chemotherapy in lung cancer invitro and significantly reduces tumor burden in a murine lung cancer model. This study suggests a role for ASI therapy in the treatment of lung cancer.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.